Comparing liver transplant methods for colorectal cancer patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study examines the clinical outcomes of various liver transplant methods for patients with unresectable liver metastases from colorectal cancer. It compares living versus deceased donor transplants, whole organ versus split liver transplants, and one-stage versus two-stage procedures. The study will assess factors such as hospital recovery times and one-year survival rates post-transplant. Additionally, blood samples will be collected for future research purposes. All methods being evaluated are standard practices approved by the United Network of Organ Sharing.

Why it matters

Who can join: the full rules

Inclusion:

1. All Patients of either gender ≥ 18 years of age who are listed for Liver transplant candidates at Northwestern with liver metastases due to colorectal cancer (CRLM).
2. Subjects must be able to provide informed consent themselves and without the use of a legally authorized representative (LAR), to be determined by the PI or Sub-I at the time of Consent.

Exclusion:

1. Adults unable to consent
2. Pregnant Women
3. Certain clinical/surgical/anatomical parameters, at the discretion of the PI.

Where it's running

• Northwestern University-Comprehensive Transplant Center
  Chicago, Illinois, United States Recruiting

Study contacts

• Study coordinator: Yajaira Navarro
• Email: a-daud@northwestern.edu
• Phone: 312-694-2092

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Dexcom G7 CGM in critically ill adults after major abdominal surgery or solid organ transplant

  This study tests how accurately the Dexcom G7 continuous glucose monitor tracks glucose in ICU patients after major abdominal surgery or solid organ transplantation who need tight insulin control.

  Recruiting Institute for Clinical and Experimental Medicine · Prague · NCT07611721

• Metastatic liver cancer patient registry from multiple Chinese centers

  This is a registry that collects real-world data on adults with liver metastases to understand patterns and prognosis and to support future research.

  Recruiting at 2 sites Anhui Provincial Hospital · Bengbu, Anhui and 2 other locations · NCT07602504

• Combination of balstilimab, botensilimab, and agenT-797 in pMMR colorectal cancer with liver metastases

  This trial tests whether a three-drug combination can help adults with metastatic, MSS colorectal cancer that has spread to the liver.

  Recruiting Phase 2 Scripps Health · La Jolla, California · NCT07550088

• Preoperative Carbohydrate Loading Before Liver Transplant

  This study tests whether drinking a carbohydrate beverage before anesthesia helps liver transplant patients recover faster.

  Recruiting Medical University of Warsaw · Warsaw · NCT07519057

• Dual-target CAR-NK therapy for advanced colorectal cancer with CEA, GUCY2C, or HER2 markers

  This trial tests an off-the-shelf CAR-NK cell treatment that targets two tumor markers to see if it can shrink tumors in adults with advanced or metastatic colorectal cancer whose tumors express those markers.

  Recruiting Phase 1/2 Beijing Biotech · Shenzhen, Guangdong · NCT07462650

• COLONYVAQ™: personalized quantum‑classical neoantigen peptide vaccine combined with chemotherapy and nivolumab for MSS stage III colorectal cancer

  This trial will test a personalized neoantigen peptide vaccine guided by quantum‑classical AI together with standard oxaliplatin‑based chemotherapy and nivolumab in patients with completely resected, microsatellite‑stable stage III colorectal cancer.

  Recruiting Early Phase 1 Biogenea Pharmaceuticals Ltd. · Thessaloniki · NCT07328087

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.